Concerning CRC, Cheng et al. reported the case of a 57-year-old Chinese patient with dMMR CRC and liver metastasis, who received as third-line treatment a combination of bevacizumab, an anti-VEGF, plus tislelizumab, an investigative anti-PD1, plus oral gut microbiota capsules. The gene discussed is PDCD1; the disease is colorectal carcinoma.